A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
3 novembre 2017 aggiornato da: Merck Sharp & Dohme LLC
A Phase I Study of Oral MK-2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors
This study will investigate the safety and tolerability of combination therapy with MK-2206 and AZD6244 (selumetinib) and determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) for this drug combination in the treatment of participants with locally advanced or metastatic solid tumors. Preliminary efficacy data will also be collected.
The primary hypotheses for this study are that: 1) the Dose-limiting Toxicities (DLTs) observed in participants with locally advanced or metastatic solid tumors after administration of combination therapy with MK-2206 and AZD6244 will be dose-dependent and allow for identification of the MTD, and 2) oral administration of combination therapy with MK-2206 and AZD6244 to participants with advanced solid tumors will be generally well-tolerated.
Panoramica dello studio
Stato
Completato
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
63
Fase
- Fase 1
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Participant has confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or therapies known to provide clinical benefit, or for whom efficacious standard therapy or any other therapy known to provide clinical benefit does not exist
- Participant has no history of prior cancer, except certain cervical, skin, or prostate cancers, or has undergone potentially curative therapy with no evidence of disease for 5 years
- At least 18 years of age
- Participant is able to swallow oral medications
- For participants enrolled in the MTD expansion cohorts, must have a diagnosis of Kirsten rat sarcoma viral oncogene homolog (KRAS) tumor-type non small-cell lung cancer (NSCLC). Additional tumor types (with specific mutations) may be added to the MTD expansion cohorts after discussion between Sponsor and Investigator
Exclusion Criteria:
- Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks of entering the study
- Participant is currently participating in or has participated in a study of an investigational compound or device within 30 days or 5x the compound's half-life of Cycle 1, Day 1
- Participant has known central nervous system metastases and/or carcinomatous meningitis
- Participant has a primary central nervous system tumor or spinal cord compression
- Participant is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse
- Participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study
- Participant is human immunodeficiency virus (HIV) positive
- Participant is has history of hepatitis B or C or active hepatitis A
- Participant has a history or current evidence of heart disease
- Participant has uncontrolled high blood pressure
- Participant has poorly controlled diabetes
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: MK-2206 45 mg QOD + AZD6244 75 mg QD
Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 45 mg QOD + AZD6244 75 mg BID
Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 90 mg QW + AZD6244 50 mg BID
Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 90 mg QW + AZD6244 75 mg QD
Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 90 mg QW + AZD6244 75 mg BID
Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 90 mg QW + AZD6244 100 mg QD
Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 90 mg QW + AZD6244 150 mg QD
Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 100 mg QW + AZD6244 100 mg QD
Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
|
Sperimentale: MK-2206 135 mg QW + AZD6244 100 mg QD
Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
|
Oral tablets
Oral capsules
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With a Dose-limiting Toxicity (DLT)
Lasso di tempo: Cycle 1 (Up to 28 days)
|
Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
DLTs included: Grade 4 neutropenia lasting for ≥7 days; Grade 3 or Grade 4 neutropenia with fever >38.5ºC and/or infection requiring antibiotic or anti-fungal treatment; Grade 4 thrombocytopenia (≤25.0 x 10^9/L); Grade ≥3 non-hematologic toxicity with exceptions; Any drug-related AE, regardless of CTCAE Grade, leading to a dose modification of MK-2206 or AZD6244; Unresolved CTCAE Grade ≥3 drug-related toxicity requiring drug interruption for >14 days; ≥ Grade 3 signs or symptoms of glucose intolerance and accompanied by ≥ Grade 2 hyperglycemia (glucose >160 dL or 8.9 mmol/L); ≥ Grade 3 electrolyte abnormalities due to glucose intolerance and not attributable to another cause; Diagnosis of lactoacidosis or ketoacidosis; Persistent increases in corrected QT (QTc) interval (>60 msec from baseline and/or >500 msec); Clinically significant bradycardia.
|
Cycle 1 (Up to 28 days)
|
|
Number of Participants Who Experienced at Least One Adverse Event (AE)
Lasso di tempo: Up to approximately 23 months
|
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study drug, whether or not considered related to the use of the product.
Any worsening of a pre-existing condition which was temporally associated with the use of study drug was also an AE.
The number of participants who experienced at least one AE is presented.
|
Up to approximately 23 months
|
|
Number of Participants Who Discontinued Study Treatment Due to an AE
Lasso di tempo: Up to approximately 20 months
|
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study drug, whether or not considered related to the use of the product.
Any worsening of a pre-existing condition which was temporally associated with the use of study drug was also an AE.
The number of participants who discontinued study treatment due to an AE is presented.
|
Up to approximately 20 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With a Tumor Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Lasso di tempo: Baseline and after every 8 weeks of treatment until documentation of objective response or disease progression (Up to 2 years)
|
Radiological evaluation (via computed tomography [CT] or magnetic resonance imaging [MRI]) of tumor response was assessed every 8 weeks post-treatment during Cycles 1-6, and per institutional standard of care in Cycle 7 and beyond.
The best overall tumor response was the best response based on RECIST 1.1 recorded from the start of the study treatment until the end of treatment.
Response categories included: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Participants whose tumor was not evaluable (NE) were missing a valid RECIST1.1 measurement at baseline.
The best overall tumor response for participants is presented.
|
Baseline and after every 8 weeks of treatment until documentation of objective response or disease progression (Up to 2 years)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
23 novembre 2009
Completamento primario (Effettivo)
26 novembre 2012
Completamento dello studio (Effettivo)
16 luglio 2014
Date di iscrizione allo studio
Primo inviato
25 novembre 2009
Primo inviato che soddisfa i criteri di controllo qualità
25 novembre 2009
Primo Inserito (Stima)
30 novembre 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
7 agosto 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
3 novembre 2017
Ultimo verificato
1 novembre 2017
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2206-010
- 2009_698 (Altro identificatore: Merck Registration Number)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Sì
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su MK-2206
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCCompletatoPANCREAS | NeuroendocrinoStati Uniti
-
Dana-Farber Cancer InstituteMemorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... e altri collaboratoriRitirato
-
Merck Sharp & Dohme LLCCompletatoNeoplasie | Cancro | Tumori solidi metastatici | Tumori localmente avanzati
-
Merck Sharp & Dohme LLCTerminato
-
Merck Sharp & Dohme LLCCompletato
-
National Cancer Institute (NCI)Attivo, non reclutanteMelanoma cutaneo di stadio III AJCC v7 | Melanoma cutaneo di stadio IV AJCC v6 e v7 | Neoplasia solida maligna avanzata | Melanoma cutaneo in stadio IIIC AJCC v7 | Cancro a cellule renali in stadio III AJCC v7 | Cancro a cellule renali in stadio IV AJCC v7 | Melanoma cutaneo in stadio IIIA AJCC v7 | Melanoma cutaneo in stadio IIIB AJCC... e altre condizioniStati Uniti
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCTerminatoCancro rettale | Cancro al colonStati Uniti
-
UConn HealthMedical College of WisconsinCompletatoColite ulcerosaStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteCarcinoma prostatico ricorrente | Cancro alla prostata in stadio IIA AJCC v7 | Cancro alla prostata in stadio III AJCC v7 | Cancro alla prostata in stadio I AJCC v7 | Cancro alla prostata in stadio IIB AJCC v7Stati Uniti, Irlanda
-
King's College LondonWashington Red Raspberries CommissionReclutamento